Want to see PIII full AI Analyst Report?
PIII Stock Chart & Stats
$3.50
-$0.01(-4.21%)
At close: 4:00 PM EST
$3.50
-$0.01(-4.21%)
Day’s Range― - ―
52-Week Range$1.52 - $16.89
Previous CloseN/A
Volume132.39K
Average Volume (3M)7.40K
Market Cap
$73.10M
Enterprise Value$73.76M
Total Cash (Recent Filing)$25.50M
Total Debt (Recent Filing)$62.27M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 11, 2026EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.55
Shares Outstanding3,325,858
10 Day Avg. Volume4,406
30 Day Avg. Volume7,400
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.07
Price to Sales (P/S)0.00782
P/FCF Ratio-0.13
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.10
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$488.00Price Target Upside13842.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.08
Revenue Forecast (FY)$1.52B
Bulls Say, Bears Say
Bulls Say
EBITDA Expansion TargetsManagement's pursuit of $120 million to $170 million in EBITDA expansion opportunities indicates clear targets for profit growth if execution stays on track.
Operational ImprovementsManagement highlighted the operational improvement plan is embedded and has produced over $100 million in EBITDA improvement, supporting ongoing margin recovery.
Risk Adjustment And Clinical ScalingFocused initiatives in risk coding, clinical program scaling, and contract enhancements could increase reimbursement capture and operational leverage, contributing to EBITDA growth.
Bears Say
Margin PressurePersistent margin pressure and remaining earnings challenges suggest profitability may stay under strain despite some operational gains.
Revenue ShortfallRevenue weakness in the first half of the year points to top-line challenges that could constrain cash flow and investor confidence until growth stabilizes.
Unfavorable Settlements And AdjustmentsUnfavorable mid-year settlements and intra-year adjustments that widened adjusted EBITDA losses create uncertainty about near-term earnings and forecasting.
P3 Health Partners News
PIII FAQ
What was P3 Health Partners’s price range in the past 12 months?
P3 Health Partners lowest stock price was $1.52 and its highest was $16.89 in the past 12 months.
What is P3 Health Partners’s market cap?
P3 Health Partners’s market cap is $73.10M.
When is P3 Health Partners’s upcoming earnings report date?
P3 Health Partners’s upcoming earnings report date is Aug 11, 2026 which is in 33 days.
How were P3 Health Partners’s earnings last quarter?
P3 Health Partners released its earnings results on May 14, 2026. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of -$4.85 by $5.17.
Is P3 Health Partners overvalued?
According to Wall Street analysts P3 Health Partners’s price is currently Undervalued.
Does P3 Health Partners pay dividends?
P3 Health Partners does not currently pay dividends.
What is P3 Health Partners’s EPS estimate?
P3 Health Partners’s EPS estimate is -1.9.
How many shares outstanding does P3 Health Partners have?
P3 Health Partners has 3,325,858 shares outstanding.
What happened to P3 Health Partners’s price movement after its last earnings report?
P3 Health Partners reported an EPS of $0.32 in its last earnings report, beating expectations of -$4.85. Following the earnings report the stock price went up 180.149%.
Which hedge fund is a major shareholder of P3 Health Partners?
Currently, no hedge funds are holding shares in PIII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
P3 Health Partners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$488.00 (13842.86% Upside)
$488.00 (13842.86% Upside)
Hedge Fund Trend
Decreased
By 1.8K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-63.88%
12-Months-Change
Fundamentals
Return on Equity
184.97%
Trailing 12-Months
Asset Growth
-14.00%
Trailing 12-Months
Company Description
P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. The company operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
PIII Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a materially improved operating trajectory with a clear shift to positive adjusted EBITDA, stronger Medicare Advantage funding (~15% YoY), deeper provider alignment (Tier 1 up to 62%) and disciplined cost management producing a flat MA medical trend versus industry inflation. These operational and contractual wins supported a raised outlook and meaningful capital structure actions that improve equity compliance. Counterbalancing these positives were a roughly 10% decline in at-risk membership (by design), limited cash ($25M), reliance on $17M of favorable prior-year development (underlying adjusted EBITDA ~$8M), a relatively high adjusted medical loss ratio (~85.2%), and continued execution risk tied to achieving broader delegation and managing claims development. On balance, the quarter demonstrates improving fundamentals and credible progress, while still requiring execution on multi-year delegation and capital stability initiatives.View all PIII earnings summariesPIII Stock 12 Month Forecast
Average Price Target
$488.00
▲(13842.86% Upside)
Technical Analysis
Ownership Overview
77.52% Insiders
14.32% Mutual Funds
1.15% Other Institutional Investors
5.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---